European healthcare organisations have called for a ‘robust and transparent framework’ for Health Technology Assessment (HTA) to allow the industry to manage its resources more effectively. This will encourage the development of new and innovative technologies for the benefit of patients and society, they say.
The call is featured in a joint paper produced by organisations including the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Generic Medicines Association (EGA) and the European Association for Bioindustries (EuropaBio).
Their jointly developed paper The value of industry involvement in HTA was presented at the European HTA network EUnetHTA’s conference in Gdansk. The paper say industry is a ‘valuable partner’ in the HTA process, but needs greater support from the EUnetHTA.
The organisations also describe the stages of the HTA process where industry could add value and citing early industry involvement with the UK National Institute for Health and Clinical Excellence ‘s (NICE) evaluation pathway for medical devices and diagnostics as an example of successful collaboration. Specific technology assessments and their constituent phases were also recognised as an area for positive industry involvement. This included the data gathering and pre-submission discussion stage, when industry organisations can clarify or methodological guidance.
The assessment of evidence and production of recommendation stage was another area for further involvement. This could provide an opportunity for manufacturers to discuss their HTA submissions with regulatory agencies to enhance the quality of specific assessments by giving further opportunities to discuss study designs and models.
In a joint statement, all involved organisations said: “The healthcare industry looks forward to continue working with the EUnetHTA Joint Action to ensure that the European collaboration on HTA is a success. This includes making sure that industry is fully involved in the policy discussions within that forum as well as in the future pilots that will be taken on going forward.”
The call is featured in a joint paper produced by organisations including the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Generic Medicines Association (EGA) and the European Association for Bioindustries (EuropaBio).
Their jointly developed paper The value of industry involvement in HTA was presented at the European HTA network EUnetHTA’s conference in Gdansk. The paper say industry is a ‘valuable partner’ in the HTA process, but needs greater support from the EUnetHTA.
The organisations also describe the stages of the HTA process where industry could add value and citing early industry involvement with the UK National Institute for Health and Clinical Excellence ‘s (NICE) evaluation pathway for medical devices and diagnostics as an example of successful collaboration. Specific technology assessments and their constituent phases were also recognised as an area for positive industry involvement. This included the data gathering and pre-submission discussion stage, when industry organisations can clarify or methodological guidance.
The assessment of evidence and production of recommendation stage was another area for further involvement. This could provide an opportunity for manufacturers to discuss their HTA submissions with regulatory agencies to enhance the quality of specific assessments by giving further opportunities to discuss study designs and models.
In a joint statement, all involved organisations said: “The healthcare industry looks forward to continue working with the EUnetHTA Joint Action to ensure that the European collaboration on HTA is a success. This includes making sure that industry is fully involved in the policy discussions within that forum as well as in the future pilots that will be taken on going forward.”
Φαρμακευτικο Μαρκετινγκ: Θεωρια, Πρακτικη, Δεοντολογια
The ultimate guide for Pharma Marketing
Champions
Ζητήστε
το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…